In vivo activity assessment of a concentrated AXO-AAV-OPMD clinical construct that simultaneously expresses anti-PABN1 shRNA and a codon optimized PABPN1

  • Popplewell, Linda (PI)

Project: Research

Project Details

StatusFinished
Effective start/end date1/12/18 → 20/09/19

Funding

  • Axovant Sciences Inc: £194,748.00